Zhu XW, Zhang CX, Xu TH, Jiang GN, Yao L. Efficacy of roxadustat in treatment of peritoneal dialysis patients with renal anaemia. World J Clin Cases 2021; 9(26): 7682-7692 [PMID: 34621819 DOI: 10.12998/wjcc.v9.i26.7682]
Corresponding Author of This Article
Li Yao, MD, PhD, Director, Professor, Department of Nephrology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing Bei Street, Heping District, Shenyang 110001, Liaoning Province, China. liyao_cmu@163.com
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Sep 16, 2021; 9(26): 7682-7692 Published online Sep 16, 2021. doi: 10.12998/wjcc.v9.i26.7682
Efficacy of roxadustat in treatment of peritoneal dialysis patients with renal anaemia
Xin-Wang Zhu, Cong-Xiao Zhang, Tian-Hua Xu, Guan-Nan Jiang, Li Yao
Xin-Wang Zhu, Tian-Hua Xu, Guan-Nan Jiang, Li Yao, Department of Nephrology, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Cong-Xiao Zhang, Blood Purification Center, The Fourth People’s Hospital of Shenyang, Shenyang 110031, Liaoning Province, China
Author contributions: Zhu XW designed and performed the research; Zhang CX, Xu TH, and Jiang GN contributed to data analysis; Zhu XW wrote the paper; Yao L revised the paper.
Supported byLiaoning Province Key R&D Guidance Program, No. 2019JH8/10300016; and Liaoning Province Grassroots Health and Family Planning Appropriate Technology Promotion Project, No. LHATP-201801.
Institutional review board statement: The protocol of this study was approved by the Ethics Committee of The First Affiliated Hospital of China Medical University. All procedures performed in studies involving human participants were conducted in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Informed consent statement: Written informed consent was obtained from all patients.
Conflict-of-interest statement: All authors have no conflicts of interest related to the manuscript.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li Yao, MD, PhD, Director, Professor, Department of Nephrology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing Bei Street, Heping District, Shenyang 110001, Liaoning Province, China. liyao_cmu@163.com
Received: February 23, 2021 Peer-review started: February 23, 2021 First decision: March 25, 2021 Revised: April 2, 2021 Accepted: July 27, 2021 Article in press: July 27, 2021 Published online: September 16, 2021 Processing time: 198 Days and 22.3 Hours
ARTICLE HIGHLIGHTS
Research background
There are no studies on the use of roxadustat in patients on regular peritoneal dialysis in China.
Research motivation
The recombinant human erythropoietin (EPO) is mainly used to treat renal anemia in peritoneal dialysis patients, but the treatment compliance rate is not satisfactory.
Research objectives
Roxadustat (hypoxia-inducible factor prolyl hydroxylase inhibitor) is a new generation of oral anaemia treatment drug that can effectively correct renal anaemia in non-dialysis and hemodialysis patients. We aimed to research if roxadustat could further improve the compliance of anemia treatment in peritoneal dialysis patients.
Research methods
This was a retrospective study to evaluate the efficacy of roxadustat in the treatment of peritoneal dialysis patients with renal anaemia. A before-and-after self-control design was performed on 31 patients treated with recombinant human EPO followed by roxadustat.
Research results
The haemoglobin (Hb) compliance rate was 16.1% during the EPO phase and 67.7% during the roxadustat phase. Roxadustat also affected the iron reserves and blood lipids. No major adverse cardiovascular events or exacerbation of hypertension occurred in any patient.
Research conclusions
The application of roxadustat in peritoneal dialysis patients with renal anaemia can effectively improve the Hb compliance rate.
Research perspectives
Roxadustat could safely and effectively improve the anemia in peritoneal dialysis patients, and the mechanisms underlying the effects on or interactions with lipids, iron reserves, and inflammation require further clarification.
